Access to Medicines

Access to Medicines

The Big Pharma Bullies: Secrecy for Vaccine Supplies in a Pandemic 

Access to Medicines

Hearing Testimony: COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TR... 

Access to Medicines

COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexi... 

Access to Medicines

TRIPS-Compliant Alternatives for Overcoming Intellectual Property Barriers to CO...  

Access to Medicines

Letter to ViiV re CAB-LA for PrEP  

Access to Medicines

BMJ Global Health: A pandemic treaty for equitable global access to medical coun...  

Access to Medicines

Letter to Pres. Biden on COVID19 Global Summit May 2022 

Access to Medicines

Amicus Brief on Human Rights Principles and TRIPS-Compliant Interpretation to th... 

Access to Medicines

Policy Brief: Community-Based COVID-19 Test-and-Treat (April 2022) 

Access to Medicines

Community-Based Test-and-Treat 

Access to Medicines

To Save Lives, a COVID Intellectual Property Waiver Must Cover Medicines and Oth... 

Access to Medicines

Request of Least Developed Countries for Extension of Transition Period 

Access to Medicines

Policy Brief: Third-Way Proposals from Big Pharma and the WTO are the Same-Old W... 

Access to Medicines

COVID-19 Emergency Supplemental Spending and the U.S. Global AIDS Response 

Access to Medicines

Webinar: How YOU Can Increase COVID-19 Vaccine Access Worldwide  

Access to Medicines

Letter to CEOs of Pharma Companies Producing COVID19 Vaccines 

Access to Medicines

CSO Letter to Gavi Board 

Access to Medicines

Health GAP’s Testimony for U.S. House Committee on Oversight and Reform 

Access to Medicines

Policy Brief: Dolutegravir in Southern & Eastern Africa and the Right to Ch...